Clinical Trial Search

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Change in Hemoglobin A1c — 2.67; 1.05 percentage change from baseline

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min

Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05

Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Primary: Mean Weekly Blood Glucose — 187; 178 mg/dL

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants

Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Feasibility of Usage — 168 minutes/week

Primary: ISR in Response to a Glucose Clamp and Oral Glucose Ingestion Before and After 2 Months of Insulin Treatment to Improve Average Glycemia. — 0.67; 0.75; 1.11; 0.76 pmol/min

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Either Insulin Detemir Mixed With Rapid Acting Insulin (RAI) or…

Primary: Residual Beta-cell Function (RBCF) — 1.78; 2.27; 1.56; 1.76 ng/ml — p=<0.001

Primary: HbA1c Value After 28 Days — 7.94; 8.72 HbA1c %

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL

Primary: Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c. — 9.0; 8.9; 0.2; 0.2 percentage

Primary: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 — -0.21; -0.21 nanomoles per…

Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43

Primary: Percentage of Time in Target Range of 70-180 mg/dL. — 49.64; 48.86; 60.78; 50.1 percent time spent 70 mg/dL - 180 mg/dL

Primary: Mean Change From Baseline in Time Normalized Stimulated (From Mixed Meal Tolerance Test [MMTT]) 2-hour Plasma C-peptide Area Under the Curve (AUC) at Week 52 — -0.16…

Primary: Number of Participants Experiencing an Adverse Event (AE) — 6; 6; 0; 4 Participants

Primary: Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an…